JP2008535850A5 - - Google Patents

Download PDF

Info

Publication number
JP2008535850A5
JP2008535850A5 JP2008505580A JP2008505580A JP2008535850A5 JP 2008535850 A5 JP2008535850 A5 JP 2008535850A5 JP 2008505580 A JP2008505580 A JP 2008505580A JP 2008505580 A JP2008505580 A JP 2008505580A JP 2008535850 A5 JP2008535850 A5 JP 2008535850A5
Authority
JP
Japan
Prior art keywords
day
flumazenil
administered
pharmaceutical composition
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008505580A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008535850A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/013099 external-priority patent/WO2006110557A2/en
Publication of JP2008535850A publication Critical patent/JP2008535850A/ja
Publication of JP2008535850A5 publication Critical patent/JP2008535850A5/ja
Pending legal-status Critical Current

Links

JP2008505580A 2005-04-07 2006-04-07 物質乱用及び依存の治療方法 Pending JP2008535850A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66903305P 2005-04-07 2005-04-07
US72897905P 2005-10-21 2005-10-21
US72901305P 2005-10-21 2005-10-21
PCT/US2006/013099 WO2006110557A2 (en) 2005-04-07 2006-04-07 Methods for the treatment of substance abuse and dependence

Publications (2)

Publication Number Publication Date
JP2008535850A JP2008535850A (ja) 2008-09-04
JP2008535850A5 true JP2008535850A5 (https=) 2009-01-15

Family

ID=37087555

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008505625A Withdrawn JP2008538748A (ja) 2005-04-07 2006-04-06 不安、物質乱用及び依存の予防のための改良型方法及び組成物
JP2008505580A Pending JP2008535850A (ja) 2005-04-07 2006-04-07 物質乱用及び依存の治療方法
JP2008505599A Pending JP2008535852A (ja) 2005-04-07 2006-04-07 不安関連障害の治療方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008505625A Withdrawn JP2008538748A (ja) 2005-04-07 2006-04-06 不安、物質乱用及び依存の予防のための改良型方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008505599A Pending JP2008535852A (ja) 2005-04-07 2006-04-07 不安関連障害の治療方法

Country Status (12)

Country Link
US (3) US20080207601A1 (https=)
EP (3) EP1868593A2 (https=)
JP (3) JP2008538748A (https=)
KR (2) KR20080004581A (https=)
AU (3) AU2006235318A1 (https=)
BR (2) BRPI0609744A2 (https=)
CA (3) CA2604887A1 (https=)
CR (2) CR9410A (https=)
IL (2) IL186450A0 (https=)
MX (2) MX2007012355A (https=)
NO (2) NO20075161L (https=)
WO (3) WO2006110642A2 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192271A1 (en) 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
EP1868593A2 (en) * 2005-04-07 2007-12-26 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
US20090269795A1 (en) * 2007-03-09 2009-10-29 The Research Foundation Of State University Of New York Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability
JP5513378B2 (ja) * 2007-06-15 2014-06-04 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイテッド 治療化合物
US8486448B2 (en) 2007-12-17 2013-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
ITRM20080436A1 (it) * 2008-08-06 2010-02-07 Francesco Marrosu Uso della finasteride e di altre sostanze inibenti l'enzima 5-a-reduttasi per la prevenzione e la cura dei disturbi dell'impulso e dell'aggressivita'
TWI541246B (zh) 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
AU2009327312A1 (en) 2008-12-16 2011-08-04 Labopharm Europe Limited Misuse preventative, controlled release formulation
EP2398475B1 (en) * 2009-02-20 2017-12-13 Palmaya Pty Ltd Pharmaceutical preparation and delivery system
WO2011073985A1 (en) * 2009-12-14 2011-06-23 Coeruleus Ltd. Compositions and methods of counteracting residual sedative effects of sleep/ hypnotic drugs
WO2011087755A2 (en) * 2009-12-22 2011-07-21 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
AU2011279557B2 (en) * 2010-07-16 2018-09-27 Verita Research Pte Ltd Pharmaceutical compositions for sustained delivery of benzodiazepine antagonists
US8968722B2 (en) * 2010-12-29 2015-03-03 Mead Johnson Nutrition Company Milk-based nutritional compositions containing lactoferrin and uses thereof
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
MX2015002252A (es) * 2012-08-21 2015-07-21 Sage Therapeutics Inc Metodos para tratar epilepsia o estado de epilepsia.
DK2925327T3 (da) 2012-11-30 2024-03-25 Univ California Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression
MX365644B (es) * 2012-12-18 2019-06-10 Univ Washington Esteroides neuroactivos sustituidos con 19-alcoxi-17, profarmacos de los mismos, y metodos de tratamiento usando los mismos.
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
EP3160969B1 (en) * 2014-06-26 2023-09-13 The Johns Hopkins University Peripherally restricted gaba positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
HK1258616A1 (zh) 2016-03-08 2019-11-15 Sage Therapeutics, Inc. 神经活性类固醇、组合物、及其用途
US20180050005A1 (en) * 2016-08-16 2018-02-22 Janssen Pharmaceutica Nv Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
DK3565528T3 (da) * 2017-01-09 2025-05-26 Relmada Therapeutics Inc Injicerbare suspensioner
GB201704909D0 (en) 2017-03-28 2017-05-10 Ldn Pharma Ltd Cancer therapy
AU2018244806B2 (en) * 2017-03-28 2023-12-21 LDN Pharma Limited An agent that increases the expression of the Bcl2-associated agonist of cell death for the treatment of cancer
KR101898814B1 (ko) 2017-09-07 2018-09-13 백창목 도어 개폐용 도어록
WO2019055942A1 (en) * 2017-09-18 2019-03-21 SEN-JAM Pharmaceutical LLC METHODS AND COMPOSITIONS FOR INHIBITING OPIOID TOLERANCE
CA3076193A1 (en) * 2017-09-18 2019-03-21 SEN-JAM Pharmaceutical LLC Methods and compositions to inhibit symptoms associated with opioid withdrawal
WO2019060171A1 (en) * 2017-09-20 2019-03-28 Calista Capital, Llc METHOD FOR STOPPING TOBACCO
US12414956B2 (en) 2017-09-20 2025-09-16 Calista Capital, Llc Method for smoking cessation
EP3482751A1 (en) * 2017-11-14 2019-05-15 LDN Pharma Limited Cancer treatment
MX2020010219A (es) * 2018-04-05 2020-11-09 Asarina Pharma Aps Antagonistas de gaba-a para tratar trastornos por abstinencia de sustancia.
MX2020010545A (es) * 2018-04-06 2021-01-08 Ovid Therapeutics Inc Uso de gaboxadol en el tratamiento de trastornos por consumo de sustancias.
MX2021003302A (es) 2018-09-20 2021-05-13 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del sindrome de tourette, los tics y la tartamudez.
US20220152044A1 (en) * 2019-03-14 2022-05-19 Palmaya Pty Ltd Treatment of inflammatory diseases of the central nervous system
BR112022003686A2 (pt) * 2019-08-26 2022-05-24 Period Pill Bv Tratamento de sintomas induzidos pelo ciclo menstrual
US12233070B2 (en) 2020-06-30 2025-02-25 University Of Mississippi Medical Center Methods for treating benzodiazepine misuse/use disorder
IL303117A (en) 2020-11-27 2023-07-01 Trexapharm Pty Ltd Preparations containing flumazenil and naltrexone and methods of using them
US20220265601A1 (en) * 2021-02-10 2022-08-25 David Alan Heldreth, JR. Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses.
US12396981B2 (en) 2023-03-09 2025-08-26 William Shulman Methods of using DMT

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034087A (en) * 1973-12-17 1977-07-05 The Regents Of The University Of Michigan Pharmaceutical composition and process of treatment
US4595684A (en) * 1985-08-16 1986-06-17 Ciba-Geigy Corporation Method of suppressing benzodiazepine induced sedation with 2-(p-methoxypenyl)-pyrazolo[4,3-c]quinolin-3(5H)-one or a salt thereof
US5175155A (en) * 1991-10-07 1992-12-29 Sterling Winthrop Inc. Win 49596-finasteride method of use and compositions
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
FR2719843B1 (fr) * 1994-05-10 1996-06-07 Synthelabo Dérivés de 5,6-dihydro-4h-imidazo [2',1':2,3] imidazo-[4,5,1-ij] quinoléine et de 4,5-dihydroimidazo [1,2-a] pyrrolo-[1,2,3-cd] benzimidazole, leur préparation et leur application en thérapeutique.
US5521181A (en) * 1995-01-27 1996-05-28 Abbott Laboratories Bicyclic substituted hexahydrobenz[e]isoindole α-1 adrenergic antagonists
IT1274481B (it) * 1995-05-12 1997-07-17 Indena Spa Composizioni farmaceutiche per il trattamento della alcol-dipendenza
BR9812144A (pt) * 1997-08-28 2000-07-18 Janus Pharmaceuticals Inc Antagonistas da atividade de androgen como terapias para anorexia, anorexia nervosa e distúrbios caracterizados por uma condiçao de baixo peso patológica
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
WO1999061014A2 (en) 1998-05-28 1999-12-02 Sepracor Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
AU7331300A (en) * 1999-08-27 2001-03-26 Merck & Co., Inc. Method for treating or preventing chronic prostatitis or chronic pelvic pain syndrome
WO2002056964A1 (es) * 2001-01-17 2002-07-25 Hythiam, Inc. Empleo de flumazenilo en la elaboración de una medicación para el tratamiento de la dependencia de alcohol
US20020173495A1 (en) * 2000-08-24 2002-11-21 Dalton James T. Selective androgen receptor modulators and methods of use thereof
CA2436511C (en) * 2001-02-15 2009-08-04 Juan Jose Legarda Ibanez Use of flumazenil to produce a medicament for the treatment of cocaine dependency
GB0311859D0 (en) * 2003-05-22 2003-06-25 Merck Sharp & Dohme Therapeutic agents
US20050176680A1 (en) * 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
EP1868593A2 (en) 2005-04-07 2007-12-26 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence

Similar Documents

Publication Publication Date Title
JP2008535850A5 (https=)
Kask et al. Anxiogenic-like effect of the neuropeptide Y Y1 receptor antagonist BIBP3226: antagonism with diazepam
JP2007512371A5 (https=)
DK2206498T3 (da) Blandede ORL1/[mu]-agonister til smertebehandling
JP6753860B2 (ja) リルゾールの舌下製剤
JP2010513569A5 (https=)
TW200840573A (en) Heterocyclic compounds and their methods of use
WO2008050329A3 (en) Novel sirnas and methods of use thereof
WO2007092416A3 (en) Melanin concentrating hormone receptor-1 antagonists
MX356965B (es) Composiciones y metodos para profilaxis y tratamiento de adicciones.
JP2010537990A5 (https=)
JP2014506321A5 (https=)
JP2011502995A (ja) アンドログラフィス・パニキュラータ抽出物
WO2008039431A3 (en) Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
KR20170137030A (ko) 릴루졸의 설하 투여
MA26964A1 (fr) Association d'agonistes de gaba et d'inhibiteurs de sorbitol-deshydrogenase.
JP2002506815A (ja) ＧＡＢＡＡα５逆作動薬とアセチルコリンエステラーゼ阻害剤との組合わせ
WO2008087491A8 (en) Method for treating or preventing symptoms of hormonal variations
JP2007510736A5 (https=)
JP2002516282A5 (https=)
FR2757400A1 (fr) Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs
JP2018503677A (ja) 神経精神系障害の治療のための組成物および方法
WO2007114902A3 (en) Alkylthiobenzylpiperidine compounds
JP2005503383A5 (https=)
AU2003214535A8 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists